TORONTO and HAIFA, Israel, Jan. 08, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (NRX:CA), (OTCQB: NRXBF), (Germany: J90) ("NurExone" or the "Company"), a developer of exosome-based therapies for ...
BELTSVILLE, Md., March 3, 2026 /PRNewswire/ -- REPROCELL (TYO: 4978) today announced the launch of its US FDA compliant Good Manufacturing Practice (GMP) Master Cell Bank (MCB) manufacturing service ...
Samsung Biologics said Monday it has launched in-house master cell bank production and vector construction services, strengthening its contract development orga ...
Singapore General Hospital (SGH) has entered into an agreement with pharmaceutical company Charles River Laboratories to ...
The FDA has approved more than 40 cell and gene therapy products. The regenerative medicine market is projected to reach ...
FibroBiologics, Inc. has announced the completion of its proprietary master cell bank, which will support its upcoming clinical trials. Developed in partnership with Charles River Laboratories and ...
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced an agreement with Singapore General Hospital (SGH) to provide Current Good Manufacturing ...